AccuVAC-PT0067

AccuVAC-PT0067 is an experimental **protein-based therapeutic HPV vaccine** being developed by Defence Therapeutics for **cervical cancer**. Public company materials describe it as a second HPV-focused AccuVAC program designed to **modify both the HPV E6 and E7 oncoproteins** by covalently linking them to the company's **Accum** intracellular delivery platform, with the goal of improving antigen delivery to the cytosol of antigen-presenting cells, enhancing proteasomal processing, MHC class I antigen presentation, and downstream **T-cell mediated anti-tumor immunity**. Based on the limited disclosed information, it appears intended as a **therapeutic cancer vaccine** rather than a prophylactic vaccine, but there is no clear public evidence of clinical-stage development, commercial branding, approved use, or a fully specified final formulation.